BioSpace News Archive

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, along with Elizabeth Evans, Ph.D., Chief Operating Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time.

Amedisys, Inc. announced that Chris Gerard, President and Chief Executive Officer and Scott Ginn, Executive Vice President and Chief Financial Officer, will present and conduct investor one-on-ones at the Benchmark Healthcare House Calls Conference on Thursday, June 2, the William Blair 42nd Annual Growth Stock Conference on Monday, June 6 at 2 p.m. CST and the Jefferies Healthcare Conference on Wednesday, June 8 from 3:30-3:55 p.m. ET.

Arcutis Biotherapeutics, Inc. announced results of a nationwide survey of adults with seborrheic dermatitis and the healthcare providers that treat them, designed to better understand their satisfaction and experience with currently available treatment options.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for vonoprazan.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced its management team will host a conference call following two poster presentations of PDS0101 data at 2022 American Society of Clinical Oncology Meeting (ASCO).

Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa and to advance in vivo candidate for hereditary tyrosinemia type 1 towards IND application.

Convergent Therapeutics will utilize high purity Ac-225, manufactured by IONETIX, to produce its lead asset CONV01-α.

ENDRA Life Sciences Inc. announces that the United States Patent & Trademark Office has issued a new patent to ENDRA, U.S. Patent No. 11337676 titled “Acoustically Compatible Radio-frequency Applicator Method and System.” The ‘676 patent protects ENDRA’s method and system for optimizing the delivery of radiofrequency energy to tissue using TAEUS, and serves as the parent patent for applications being prosecuted in China and in Europe.

Agenus announced that Dr. Garo Armen, Chairman and CEO of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11:30 AM EST.